# Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix™ to 18-55 Year-Old Adults

> **NCT00453986** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1352 (actual)

## Conditions studied

- Infections, Meningococcal

## Interventions

- **BIOLOGICAL:** Meningococcal vaccine GSK134612
- **BIOLOGICAL:** Mencevax™ACWY
- **BIOLOGICAL:** Fluarix™

## Key facts

- **NCT ID:** NCT00453986
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04-09
- **Primary completion:** 2007-11-30
- **Final completion:** 2008-05-21
- **Target enrollment:** 1352 (ACTUAL)
- **Last updated:** 2018-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00453986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00453986, "Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix™ to 18-55 Year-Old Adults". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00453986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*